Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06149676 · ClinicalTrials.gov registry record · Early Phase 1
A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections
A Early Phase 1 study of Recurrent Uti, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT06149676 is a Early Phase 1 study of Recurrent Uti that is actively recruiting participants, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06149676, a Early Phase 1 study of Recurrent Uti, is actively recruiting participants, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with recurrent UTI were randomized to receive either the probiotic Sacchromyces Boulardii at enrollment, and the intracellularly active Ciprofloxacin with their first UTI episode after enrollment, or they received standard of care treatment.
Conditions Studied
Interventions
- DRUG Saccharomyces Boulardii 250 MG [Florastor]
Study Locations (1)
Illinois
- Lurie Children's Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2025-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06149676
The ClinicalTrials.gov registry entry for NCT06149676 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Uti appearing as the primary indexed condition, and to 1 intervention - of which Saccharomyces Boulardii 250 MG [Florastor] is the first listed.
NCT06149676 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06149676 about?
NCT06149676 is a clinical study titled "A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections". Patients with recurrent UTI were randomized to receive either the probiotic Sacchromyces Boulardii at enrollment, and the intracellularly active Ciprofloxacin with their first UTI episode after enrollment, or they received standard of care treatment.
What is the current status of trial NCT06149676?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 35 participants. The study started on 2022-02-02. Estimated completion is 2025-12-31.
What conditions does trial NCT06149676 study?
This clinical trial studies the following conditions: Recurrent Uti.
What interventions are being tested in trial NCT06149676?
The interventions under investigation include: Saccharomyces Boulardii 250 MG [Florastor] (DRUG).
Who is sponsoring clinical trial NCT06149676?
This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06149676 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Uti
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.